AMRX Amneal Pharmaceuticals Inc

Price (delayed)

$3.27

Market cap

$990.56M

P/E Ratio

163.5

Dividend/share

N/A

EPS

$0.02

Enterprise value

$3.64B

Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in ...

Highlights
Amneal Pharmaceuticals's equity has increased by 21% YoY and by 9% QoQ
AMRX's revenue is up by 6% year-on-year
AMRX's EPS has soared by 118% year-on-year but it has dropped by 71% since the previous quarter
The company's net income has surged by 110% YoY but it has shrunk by 83% QoQ
The P/E is 60% above the last 4 quarters average of 100.9
AMRX's quick ratio is down by 19% YoY and by 7% from the previous quarter

Key stats

What are the main financial stats of AMRX
Market
Shares outstanding
302.92M
Market cap
$990.56M
Enterprise value
$3.64B
Valuations
Price to earnings (P/E)
163.5
Price to book (P/B)
2.52
Price to sales (P/S)
0.23
EV/EBIT
25.12
EV/EBITDA
9.56
EV/Sales
1.73
Earnings
Revenue
$2.1B
EBIT
$144.91M
EBITDA
$380.59M
Free cash flow
$163.11M
Per share
EPS
$0.02
Free cash flow per share
$1.09
Book value per share
$1.3
Revenue per share
$14
TBVPS
$13.85
Balance sheet
Total assets
$3.89B
Total liabilities
$3.48B
Debt
$2.87B
Equity
$391.13M
Working capital
$787.64M
Liquidity
Debt to equity
7.33
Current ratio
2.31
Quick ratio
1.26
Net debt/EBITDA
6.96
Margins
EBITDA margin
18.1%
Gross margin
35.8%
Net margin
0.1%
Operating margin
6.2%
Efficiency
Return on assets
0%
Return on equity
0.5%
Return on invested capital
3.5%
Return on capital employed
4.4%
Return on sales
6.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AMRX stock price

How has the Amneal Pharmaceuticals stock price performed over time
Intraday
1.55%
1 week
2.83%
1 month
-3.82%
1 year
-33.54%
YTD
-31.73%
QTD
2.83%

Financial performance

How have Amneal Pharmaceuticals's revenue and profit performed over time
Revenue
$2.1B
Gross profit
$751.98M
Operating income
$130.51M
Net income
$1.76M
Gross margin
35.8%
Net margin
0.1%
AMRX's net margin has surged by 111% year-on-year but it has dropped by 80% since the previous quarter
The company's net income has surged by 110% YoY but it has shrunk by 83% QoQ
The company's operating income has surged by 65% YoY but it fell by 15% QoQ
The operating margin has surged by 55% year-on-year but it has declined by 15% since the previous quarter

Growth

What is Amneal Pharmaceuticals's growth rate over time

Valuation

What is Amneal Pharmaceuticals stock price valuation
P/E
163.5
P/B
2.52
P/S
0.23
EV/EBIT
25.12
EV/EBITDA
9.56
EV/Sales
1.73
AMRX's EPS has soared by 118% year-on-year but it has dropped by 71% since the previous quarter
The P/E is 60% above the last 4 quarters average of 100.9
The price to book (P/B) is 58% lower than the 5-year quarterly average of 5.9 and 40% lower than the last 4 quarters average of 4.1
Amneal Pharmaceuticals's equity has increased by 21% YoY and by 9% QoQ
The price to sales (P/S) is 74% lower than the 5-year quarterly average of 0.9 and 43% lower than the last 4 quarters average of 0.4
AMRX's revenue is up by 6% year-on-year

Efficiency

How efficient is Amneal Pharmaceuticals business performance
Amneal Pharmaceuticals's return on equity has surged by 109% YoY but it has shrunk by 84% QoQ
The company's return on assets has shrunk by 100% QoQ but it has surged by 100% YoY
AMRX's ROIC is up by 13% YoY but it is down by 10% from the previous quarter
AMRX's ROS is down by 9% since the previous quarter but it is up by 8% year-on-year

Dividends

What is AMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMRX.

Financial health

How did Amneal Pharmaceuticals financials performed over time
AMRX's total assets is 12% greater than its total liabilities
AMRX's quick ratio is down by 19% YoY and by 7% from the previous quarter
The company's current ratio fell by 6% YoY but it rose by 3.1% QoQ
Amneal Pharmaceuticals's equity has increased by 21% YoY and by 9% QoQ
The company's debt to equity fell by 19% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.